ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Approves Novartis's Afinitor For Kidney Tumors

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Thursday granted wider approval to Novartis AG's (NVS, NOVN.VX) Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved Thursday to treat kidney tumors that are caused by a rare genetic disese called tuberous sclerosis complex, or TSC. According to FDA, the disease causes the growth of various non-cancerous tumors in the brain, kidney and other vital organs. It affects about 40,000 patients in the U.S., the majority of which develop kidney problems. TSC generally causes multiple tumors in both kidneys, which eventually cause kidney failure and bleeding. Afinitor, a pill taken once daily, blocks the uncontrolled activity of a protein called mTOR, which plays a role in the development and growth of certain tumors. Afinitor is also approved to treat certain kinds of brain and pancreatic tumors. The FDA said the approval of Afinitor for use in treating kidney tumors from TSC was based on a study involving 118 patients. About two-thirds of the patients received Afinitor and one-third were received a placebo, or fake pill. Patients receiving the placebo later had the option to receive Afinitor if their kidney tumors grew. FDA said the study showed about 42% of patients treated with Afinitor experienced "substantial" shrinkage of their tumors which lasted more than five months on average. None of the patients on the placebo had tumor shrinkage. Novartis is being required to keep following patients in the study for at least four years. FDA said the most common side effects with Afinitor were sore mouth, nausea or vomiting, skin problems, cough, headache, diarrhea, abdominal pain, joint pains, swelling of legs or arms, and upper respiratory infections. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
05/23/201512:03:02Billionaire George Soros Just Sold These 3 Stocks: Should You?
05/23/201509:09:02Will Competition Cause Teva Pharmaceutical Industries ltd. To...
05/17/201513:02:02Could This Be Healthcare's $158 Billion Black Swan Event?
05/17/201509:05:022 Stocks With Jaw-Dropping Growth Potential
05/12/201510:26:025 Largest Markets for Pharmaceuticals
05/11/201511:40:11Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/08/201515:04:02GlaxoSmithKline PLC Earnings: Pay No Attention to the Results...
05/08/201511:12:03The Best Fidelity Mutual Funds
05/07/201513:40:20Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/07/201513:34:24Court Blocks Novartis Copy of Amgen Cancer-Care Drug
05/06/201518:01:31ADR Shares End Mixed; Anheuser-Busch InBev Rises
05/06/201508:50:06GSK Cuts Return to Holders From Novartis Asset Swap
05/06/201507:58:20Genmab 1Q Sales of Arzerra Leukaemia Drug at GBP11.1 Million
05/04/201519:22:23Generic Drugs Grab Growing Market Share in Mexico--Update
05/04/201519:22:11Generic Drugs Grab Market Share in Mexico
05/04/201511:57:01Why Shares in Array BioPharma, Inc. Are Soaring Higher
05/02/201510:41:02The Best Way to Invest Money in Silicon Valley
05/01/201514:49:19Waiting for Exelixis, Inc.'s Meteor to Land
04/30/201513:47:19Teva Pharmaceutical Industries Ltd Posts Solid Quarter, Stays...
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad